In addition, a recent study in pancreatic ductal adenocarcinoma has shown that high expression of ALCAM, POU5F1B, and SMO in CTCs is associated with a worse prognosis and with an increase of stemness markers POU5F1B, CD44, and ALCAM 3 months after palliative chemotherapy [124]. The gene discussed is ALCAM; the disease is pancreatic ductal adenocarcinoma.